Summary
The aim of the study is to explore the contribution of genetic factors related either to drug metabolism (cytochrome P450 2C9) or to drug target (vitamin K epoxide reductase) to variability in the response to acenocoumarol among 222 healthy volunteers after a single oral dose. Associations between a pharmacodynamic index (reduction in Factor VII activity and INR change) and several genetic polymorphisms (VKORC1: -4931T>C, -4451C>A, -2659G>C, -1877A>G, -1639G>A, 497C>G, 1173C>T, and CYP2C9*3) were investigated using haplotype and univariate analyses. VKORC1 haplotypes were associated with the pharmacological response and this association can be explained only by the effect of the -1639G>A polymorphism (or alternatively by 1173C>T which is in complete association with it). Indeed, it explains about one third of the variability of the pharmacological response (37% of Factor VII decrease and 30% of INR change). Moreover, the previously observed effect of the CYP2C9*3 allele is independent of the VKORC1 gene effect. These two polymorphisms account for up to 50% of the inter-individual variability. The simple genotyping of two SNPs, VKORC1 -1639G>A or 1173C>T and the CYP2C9*3 polymorphisms, could thus predict a high risk of overdose before initiation of anticoagulation with acenocoumarol, and provide a safer and more individualized anticoagulant therapy.
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From
INTRODUCTION
Oral anticoagulants, including warfarin and acenocoumarol (AC), are the most widely prescribed drugs for the prevention and treatment of arterial and venous thromboembolic disorders. However, warfarin was recently identified as a causal agent in 10% of cases of all hospital admissions for adverse drug reactions in England. 1 The management of anticoagulant therapy is challenging because patients exhibit a large variability in their dose-anticoagulant effect response. A narrow range for a therapeutic effect makes individual dosing necessary.
This inter-individual variability is known to depend on environmental factors but a genetic influence has also been demonstrated. [2] [3] [4] [5] [6] The cytochrome P450 2C9 (CYP2C9) is the main enzyme responsible for the hepatic metabolism of oral anticoagulants such as acenocoumarol and warfarin. The CYP2C9 has been demonstrated to be polymorphic and its genetic variability has been shown to be associated with variations in the levels of enzyme activity. 4, 7, 8 Three major alleles have been found in humans: CYP2C9*1 (wild type or reference allele)
Cys144/Leu359, CYP2C9*2, Arg144/Leu359 and CYP2C9*3, Cys144/Ile359. [9] [10] [11] Due to an impaired metabolic capacity, patients having at least one CYP2C9*3 allele require, on average, a lower dose of AC than homozygotes for the CYP2C9*1 allele. 8, 11 Moreover, it has recently been shown in our laboratory that the CYP2C9*3 allele influences the AC response.
Up to 14% of the inter-individual variability of the AC pharmacodynamic response can be explained based on this genotypic-haplotypic approach among caucasian subjects.
12
Recent works have also suggested that genetic variations within vitamin K-dependent protein genes could also be useful for predicting anticoagulant response. [13] [14] [15] [16] The vitamin K epoxide
For personal use only. on August 16, 2017 . by guest www.bloodjournal.org From variability of the AC response based upon a seminal study showing that an intronic 1173C>T polymorphism was associated with warfarin dose requirement. Patients carrying the T allele required a lower dose of warfarin as compared with those carrying the C allele (the mean daily dose decreased 43% for homozygous TT carriers and 22% for heterozygous). 16 The aim of this study was to evaluate the contribution of genetic variability of the VKORC1 gene, in addition to the 1173 C>T polymorphism, on the pharmacodynamic outcome after AC intake.
METHODS

Subjects
The study population was the same as the one used in our previous analysis of the CYP2C9 haplotype. 12 Two hundred and sixty-three healthy volunteers between 18 and 65 years old were enrolled in this study. Among them, 230 were of caucasian origin and DNA samples were available for 222 of them (145 males and 77 females). Each subject provided written informed consent before participation. The study was approved by the «Comité consultatif pour la protection des personnes participant à la recherche biomédicale» of Pitié-Salpétrière
Hospital (local ethical committee) and complies with French bioethics laws. This study took place at the Center for Clinical investigation of Saint-Antoine University Hospital, Paris.
The CYP2C9 genotype was previously 12 determined. The observed frequencies of minor alleles CYP2C9*2 and CYP2C9*3 among the 222 subjects studied in the present setting were respectively of 0.14 and 0.086.
Methods
Selection of polymorphisms in VKORC1 gene
The VKORC1 gene polymorphisms studied in this report were selected from public databases 
Plasmid construction
To study the effect on the promoter activity of the VKORC1 -1639 G>A polymorphism, a 2171 bp fragment containing either the G (wild type) or A (mutant) allele was initially amplified from genomic DNA (isolated from subjects homozygous either for the G or A allele) with VKORC1 specific primers (5'-AGGAGATTGGTCAGCTTAATTCCAT-'3 and 5'-TAATCATCTGGCATCCTGGC-3'). Finally, a 1768 bp subfragment (-1756, -12; the nucleotides are numbered from the A in the ATG initiating translation) was obtained from the first PCR product with primers incorporating NheI and HindIII restriction sites (5'-GGAGGAGCTAGCAGGAGAGGG-3' and 5'-TATCTCAAGCTTCCGCCCG-3').
The two purified PCR products (e.g. one containing the G allele, the other the A allele) were then digested with HindIII and NheI and cloned in the pGL3 basic vector, upstream of the Results of wild type and mutant constructs were analyzed by expressing the ratio of the two luciferase activities. Renilla luciferase activity was used to normalize the transfection efficiency in all culture dishes. Each assay was repeated in four independent experiments including 6 replicates for the two constructs.
Statistics
One-way ANOVA with Dunnett's post test was performed using GraphPad Prism version 
VKORC1 haplotype analysis
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All polymorphisms were in strong linkage disequilibrium (LD) with each other. In particular, the 1173 C>T and -1639 G>A polymorphisms were in complete disequilibrium. As a consequence of this LD pattern, 7 haplotypes were inferred, among which 5 appeared with a frequency greater than 0.05 and accounted for about 95% of all chromosomes ( Table 2) .
The rare -1877 G allele seemed to be carried out by several haplotypes with very low frequency (0.007) and is therefore not depicted in Table 2 
up to 50% of the variability in the AC response. When the subject's body weight was combined with CYP2C9 and VKORC1 SNPs, an additive effect was observed, increasing the part of variability explained by these 3 parameters to 54%.
Results similar to those obtained with Factor VII ratio were observed when using INR change as the pharmacological index (e.g. 40% of variability when combining subject's weight with CYP2C9 and VKORC1 SNPs).
In table 3, the combined effects of the CYP2C9 and VKORC1 genotypes are presented and plotted against the Factor VII ratio (table 3A) The dose of AC is currently adjusted according to the INR but a large variability in the doseresponse relationship exists which explains the frequent complications: bleeding or insufficient anticoagulation. 2, [20] [21] [22] As described elsewhere 23 , these variations in doseresponse may be due partly to differences in pharmacokinetics and genetic polymorphisms in CYP2C9, as shown by the results of this and other studies 5, 12, 22 , are not the only factors involved in inter-individual differences. Indeed, AC metabolism is influenced by a number of pathologic, physiologic, and environmental factors. 2, 24 In a previous study 12 , we have shown that body weight and one CYP2C9 haplotype accounted for about 19% of the variability in the anticoagulant effect of AC. To improve and extend these findings, the VKORC1 gene was (table 2) . Haplotypic analysis revealed that the -1639 G>A polymorphism (or the pharmacological variability (~37%). It is noteworthy that the htSNPs are currently used as genetic markers (for haplotypic information) independently of the functional impact. In this case, the use of MatInspector (Genomatix Software GmbH, Munich, Germany) has revealed a potential nuclear factor 1 (NF1) binding site motif (TTGGCCA) in the VKORC1 gene at position -1639 upstream of ATG initiation codon. NF1 is an ubiquitous transcription factor known to play an important role in viral and cellular regulation and is involved in the control of constitutive and inducible gene expression. 25 Thus, a possible explanation would be that the mutation -1639G>A modifies a putative binding site for NF1 affecting VKORC1
transcription. To test this hypothesis, a luciferase reporter gene assay was performed. Our results showed no difference between the wild type and the mutant promoter. D'Andreas et al found that, the 1173C>T intronic mutation, associated with low dose requirement of warfarin, did not affect the processing of VKORC1 mRNA. 16 Altogether, these results suggested that a clear functional SNP in VKORC1 gene was not yet identified, although both SNPs were linked in the pharmacological response to anticoagulant.
The multiple linear regression analysis indicated that the genetic polymorphisms of CYP2C9
and VKORC1 strongly modulate the pharmacological response to AC with an additive effect, and, based upon our previously published data, body weight, CYP2C9 and VKORC1 accounted for about 54% for the variability. The results concerning these factors will likely have implications not only for AC but also for other oral anticoagulant treatments such as warfarin and phenprocoumon 22, 26 which are metabolized by the same enzymes and have the same targets (vitamin K dependent enzymes). Thus, the inclusion of these parameters in computer-generated algorithms to determine the initial doses of these drugs after a simple genotyping (the 2 SNPs described in this study for AC and the additional CYP2C9*2 for warfarin and phenprocoumon). Our results should be confirmed by prospective clinical studies including treated patient populations. The knowledge of the pharmacogenetics of drug metabolism and targets for vitamin K antagonists raises the possibility to individualize the initial dose and, thus, to limit the frequent complications observed with the use of these drugs.
In conclusion, the joint genotyping of two SNPs which is easy and inexpensive, CYP2C9*3 T) or the CYP2C9*3 allele. Some authors have found a weak effect of CYP2C9*2 on the dose of acenocoumarol necessary to provide the expected anticoagulation. 8, 20, 27 In this paper we did not found such difference as some other authors and as discussed in our previous paper. Table 3 Combined effect of CYP2C9 and VKORC1 genotypes on the percentage of Factor VII ratio Factor VII ratio (1A) and INR change (1B) according to VKORC1 genotype after a single oral-dose of acenocoumarol.
Factor VII ratio corresponds to remaining factor VII, expressed as a percentage compared to baseline value, before AC intake (e.g. [Factor VII 24h after AC intake / Factor VII before AC intake]x 100). 
